Literature DB >> 20627625

Epoprostenol-associated pneumonitis: diagnostic use of a T-cell proliferation assay.

Kristina T Kudelko1, Kari Nadeau, Ann N Leung, Juliana Liu, François Haddad, Roham T Zamanian, Vinicio De Jesus Perez.   

Abstract

We describe a case of severe drug-induced interstitial pneumonitis in a woman with idiopathic pulmonary arterial hypertension receiving epoprostenol confirmed by a drug T-cell proliferation assay. Proliferation assays were completed in our patient and in a healthy control. Isolated T cells were incubated with CD3-depleted peripheral blood mononuclear cells and then stimulated to proliferate with (3)H-thymidine in the presence of epoprostenol, other prostanoid analogs, and controls. A significant (p < 0.001) T-cell proliferation response occurred in our patient in the presence of epoprostenol alone. There was a trend towards an increased T-cell response to treprostinil but this was statistically insignificant. There was no significant T-cell response to the diluent alone, normal saline, iloprost, or alprostadil. There was no significant proliferation to any drug in the healthy control. Hence, a drug T-cell proliferation assay confirmed that epoprostenol can rarely incite a profound inflammatory response in the pulmonary interstitium. Copyright 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627625      PMCID: PMC2926193          DOI: 10.1016/j.healun.2010.04.023

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  17 in total

1.  Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone.

Authors:  Suleiman Kharabsheh; Catherine S Abendroth; Mark Kozak
Journal:  Am J Cardiol       Date:  2002-04-01       Impact factor: 2.778

Review 2.  Bronchoalveolar lavage in drug-induced lung disease.

Authors:  Ulrich Costabel; Esra Uzaslan; Josune Guzman
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

3.  Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin.

Authors:  S Kesten; J Dainauskas; V McLaughlin; S Rich
Journal:  Chest       Date:  1999-08       Impact factor: 9.410

Review 4.  Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1990-05

5.  Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.

Authors:  S M Palmer; L J Robinson; A Wang; J R Gossage; T Bashore; V F Tapson
Journal:  Chest       Date:  1998-01       Impact factor: 9.410

Review 6.  Interstitial lung disease induced by drugs and radiation.

Authors:  Philippe Camus; Annlyse Fanton; Philippe Bonniaud; Clio Camus; Pascal Foucher
Journal:  Respiration       Date:  2004 Jul-Aug       Impact factor: 3.580

7.  Amiodarone-induced pulmonary toxicity.

Authors:  Desak Ketut Ernawati; Leanne Stafford; Jeffery David Hughes
Journal:  Br J Clin Pharmacol       Date:  2008-05-06       Impact factor: 4.335

8.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Authors:  R J Barst; L J Rubin; W A Long; M D McGoon; S Rich; D B Badesch; B M Groves; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; L M Clayton; M M Jöbsis; S D Blackburn; D Shortino; J W Crow
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

Review 9.  Pathologic characteristics of drug-induced lung disease.

Authors:  Douglas B Flieder; William D Travis
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

10.  Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.

Authors:  Kelly M Chin; Richard N Channick; James A de Lemos; Nick H Kim; Fernando Torres; Lewis J Rubin
Journal:  Chest       Date:  2008-08-21       Impact factor: 9.410

View more
  3 in total

1.  Flow cytometric characterization of the saphenous veins endothelial cells in patients with chronic venous disease and in patients undergoing bypass surgery: an exploratory study.

Authors:  Cláudia Torres; Rui Machado; Margarida Lima
Journal:  Heart Vessels       Date:  2019-06-21       Impact factor: 2.037

2.  Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome.

Authors:  Kimikazu Takeuchi; Kazuhiko Nakayama; Mitsumasa Okano; Naoki Tamada; Hideya Suehiro; Yuto Shinkura; Kenichi Yanaka; Hiroyuki Onishi; Hidekazu Tanaka; Toshiro Shinke; Noriaki Emoto; Ken-Ichi Hirata
Journal:  Respir Med Case Rep       Date:  2017-12-07

3.  Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.

Authors:  Ayako Chida-Nagai; Koichi Sagawa; Takao Tsujioka; Takanori Fujimoto; Kota Taniguchi; Osamu Sasaki; Gaku Izumi; Hirokuni Yamazawa; Naoki Masaki; Atsushi Manabe; Atsuhito Takeda
Journal:  Heart Vessels       Date:  2020-04-13       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.